Men are more susceptible to type 2 diabetes and NAFLD than women, possibly secondary to differences in hepatic lipoprotein metabolism. The Tyneside cohort of Diabetes Remission Clinical Trial (34M/30F, 52.3±8.0 years, BMI 35.1±4.5kg/m2) were studied at baseline and to 24 months after weight loss. 3-point Dixon MRI was used for intra-organ fat. Hepatic VLDL-TG production was measured using a competitive blocking method. In the nondiabetic group, both liver and pancreas fat differed markedly in men and women (5.4± 1.1 vs. 3.4±0.1%, p=0.005, and 7.6±0.5 vs. 4.7±0.4%, p=0.0006, respectively). In diabetes, both liver and pancreas fat were similar in men and women at baseline (15.4±1.9 vs. 16.9±1.9%, p=0.57; and 8.5±0.4 vs. 8.4±0.5%, p=0.66, respectively). They decreased similarly after weight loss in both men and women (liver fat: 2.6±0.6% and 3.6±0.7%; pancreas fat: 7.6 ±0.4% and 7.5±0.5%, p<0.0001 vs. baseline for both). VLDL-TG production was also similar at baseline (554±39 vs. 559±33mg/kg/day, p=0.96) and after weight loss (418±28 vs. 448±37mg/kg/day, p=0.29). Women had a lower VLDL-TG pool size (p=0.002), lower plasma VLDL-TG (p<0.0001), lower fasting glucagon (p<0.05), higher adiponectin (p<0.001), and lower visceral adipose tissue (p<0.0001) volumes than men regardless of diabetes status. However, diabetic women had higher: subcutaneous fat (p<0.0001), leptin (p<0.0001), fasting NEFA (p=0.004), GDF-15 (p=0.044), and FGF-21 (p=0.008). After 24 months of intervention, men and women remained significantly different in VLDL-TG pool, NEFA, SAT, VAT, leptin, and adiponectin (p<0.05 for all). Women are likely to process lipoproteins more rapidly and safely store VLDL-TG. This minimizes delivery of toxic lipid metabolites from VLDL-TG to pancreatic islets. These data demonstrate important gender differences in hepatic fat handling, and underscore the importance of considering this when designing metabolic studies.


A. Al-Mrabeh: None. S. Melhem: None. S.V. Zhyzhneuskaya: None. C. Peters: Speaker’s Bureau; Self; Sanofi-Aventis. A.C. Barnes: None. K.G. Hollingsworth: None. N. Sattar: Advisory Panel; Self; Amgen, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk A/S, Pfizer Inc., Sanofi. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc. M.E. Lean: None. R. Taylor: Speaker’s Bureau; Self; Novo Nordisk Foundation.


Diabetes UK

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at